Overview
Mucolipidosis (ML) is a group of rare inherited diseases where the body cannot properly break down certain fatty substances and sugars inside cells. These materials build up in lysosomes — the cell's recycling centers — causing damage to many organs and tissues over time. There are four main types: ML I (sialidosis), ML II (also called I-cell disease), ML III (pseudo-Hurler polydystrophy), and ML IV. Each type varies in severity and the age when symptoms first appear. The buildup of these substances affects many parts of the body, including the brain, bones, eyes, heart, and liver. Common symptoms include intellectual disability, coarse facial features, bone and joint problems, vision loss, and developmental delays. ML II is generally the most severe form and often affects newborns and infants, while ML III tends to be milder and progresses more slowly. Currently, there is no cure for any type of mucolipidosis. Treatment focuses on managing symptoms and improving quality of life. This may include physical therapy, occupational therapy, special education support, and treatment for specific complications like heart or eye problems. Research into enzyme replacement and gene therapies is ongoing, giving hope for future treatments.
Key symptoms:
Intellectual disability or learning difficultiesDelayed development of motor skills like sitting, standing, and walkingCoarse or unusual facial featuresBone and joint stiffness or painShort statureVision problems, including clouding of the cornea or retinal damageEnlarged liver or spleenHeart valve problemsMuscle weakness or low muscle toneRecurrent respiratory infectionsHearing lossSeizures (in some types)Skin abnormalities
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Variable
Can begin at different ages, from infancy through adulthood
FDA & Trial Timeline
1 eventThe Children's Hospital of Zhejiang University School of Medicine — PHASE1
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Mucolipidosis.
1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Mucolipidosis.
Community
No community posts yet. Be the first to share your experience with Mucolipidosis.
Start the conversation →Latest news about Mucolipidosis
No recent news articles for Mucolipidosis.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.Which specific type of mucolipidosis does my child or I have, and how does that affect the outlook?,What genetic testing should be done, and should other family members be tested?,What specialists should be part of our care team, and how often should we see them?,Are there any clinical trials or research studies we might be eligible for?,What symptoms should prompt an emergency visit or hospital admission?,What therapies or educational supports are most important to start right away?,Are there any patient registries or support organizations we should connect with?
Common questions about Mucolipidosis
What is Mucolipidosis?
Mucolipidosis (ML) is a group of rare inherited diseases where the body cannot properly break down certain fatty substances and sugars inside cells. These materials build up in lysosomes — the cell's recycling centers — causing damage to many organs and tissues over time. There are four main types: ML I (sialidosis), ML II (also called I-cell disease), ML III (pseudo-Hurler polydystrophy), and ML IV. Each type varies in severity and the age when symptoms first appear. The buildup of these substances affects many parts of the body, including the brain, bones, eyes, heart, and liver. Common sym
How is Mucolipidosis inherited?
Mucolipidosis follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
Are there clinical trials for Mucolipidosis?
Yes — 1 recruiting clinical trial is currently listed for Mucolipidosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Mucolipidosis?
5 specialists and care centers treating Mucolipidosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.